Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide
Novo Nordisk (NVO) shares fell over 15% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s (LLY) competing treatment in a phase 3 trial, raising new concerns about its sales potential....
Seeking Alpha